ReSkript for Researchers

ReSkript's AI drafts your IIS protocol, ICF, IB, manuscript, or abstract to 90% submission-ready — in two to three hours. Referenced, structured, and ready for your review.

The real bottleneck

"You need at least a three-hour allocation of undistracted, uninterrupted attention to write on the protocol."

You can't write a protocol in 15 minutes between patients. You need the zone — and the zone is the hardest thing to find.
Clinical duties always win. The study idea is ready, but the document waits, and the timeline slips.
Every investigator-initiated study is a little different — so you rebuild the same structural sections study after study.
Manuscripts and abstracts at the end carry the same weight: finding uninterrupted time to write is the constraint.

Scientist wearing a white lab coat, blue gloves, and safety glasses holding a petri dish with blue bacterial colonies, with a microscope in the foreground.

How it works

From a concept in your head toa working draft the same afternoon.

Tell ReSkript about your study

Select the document type and enter your studydetails — design, indication, endpoints, and thedrug or intervention.

Get a near-complete draft in 2–3 hrs

The AI drafts every section — background,rationale, eligibility, endpoints, statistics —referenced to current standards.

Review, revise, and own it

Everything opens in Word. You apply your clinicaljudgment, adjust anything study-specific, andsign off.

Two scientists wearing safety glasses and lab coats working closely together in a laboratory, with scientific equipment visible around them.

What you can generate

Whatever kind of study you run, ReSkript drafts for it.

From a single case report to an adaptive Phase III — protocols, ICFs, IBs,manuscripts, abstracts, and final study reports, tailored to your study type andto FDA or EMA context.

Observational

> Case, case-control & case series
> Cohort (pro / retrospective)
> Cross-sectional
> Population studies

Interventional — drug

> Phase I, II, III
> Phase I/II, II/III
> Adaptive designs, all phases
> FDA & EMA variants

Interventional — device

> Phase I
> Phase II
> Phase III — class I
> Phase III — class II & III

Specialised

> Behavioral
> Bioequivalence
> Therapeutic equivalence
> Bioavailability

Beyond the protocol

> Informed Consent Forms (ICF)
> Investigator's Brochures (IB)
> Manuscripts & publications
> Congress abstracts

End of study

> Final study reports
> Drafted from results
> Structured to standard
> Ready for review

30+ study types · FDA & EMA context · always an editable Word file

A scientist or researcher writing notes on a clipboard in a lab surrounded by beakers and test tubes containing blue liquid.

Trust & accountability

You supervise it. You sign off. It carries your name.

ReSkript accelerates the drafting — it never takes the decision out of your hands. Responsibility for scientific accuracy and compliance stays exactly where it should: with you.

Referenced to ICH / GCP

Drafts are structured against current standards, so you startaligned instead of retrofitting.

Citations you can check

Every referenced claim links to its source — no vague orinvented citations.

Human oversight, by design

You review, revise, and approve. The investigator staysaccountable for the final work.

Disclosure-ready

AI involvement is transparent and easy to document, in line withinstitutional and journal policies.